RPL36A KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.
Images
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Form
Liquid
- Knockout validation
Sanger Sequencing
- Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1
Alternative names
60S ribosomal protein L36a, 60S ribosomal protein L44, Cell growth-inhibiting gene 15 protein, Cell migration-inducing gene 6 protein, GIG15, L36A, L44 like ribosomal protein, L44L, MGC72020, Mig-6, Migration inducing protein 6, OTTHUMP00000023680, RL36A_HUMAN, RPL44, Ribosomal protein L36a, Ribosomal protein L36a homologue, Ribosomal protein L44, dJ164F3.3
Recommended products
RPL36A KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Form
Liquid
- Knockout validation
Sanger Sequencing
- Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1
- Disease
Adenocarcinoma
- Concentration
Properties
- Gene name
RPL36A
- Gene editing type
Knockout
- Gene editing method
CRISPR technology
- Knockout validation
Sanger Sequencing
Quality control
- STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
EU: 2 US: 2
- Adherent/suspension
Adherent
- Gender
Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
Dry Ice
- Appropriate short-term storage conditions
-196°C
- Appropriate long-term storage conditions
-196°C
Notes
Recommended control: Human wild-type HeLa cell line (Human wild-type HeLa cell line ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
RPL36A also known as Ribosomal Protein L36-A or L36A is a component of the 60S ribosomal subunit. This protein has a mass of approximately 12 kDa and is widely expressed in various tissues mainly reflecting its fundamental role in cellular processes. As an essential part of the ribosome RPL36A helps facilitate the translation of messenger RNA into proteins contributing to the protein synthesis machinery which is essential for cell function and proliferation.
- Biological function summary
RPL36A is involved in the ribosome's structural integrity and function. It assumes an important role within the ribosomal large subunit by engaging in ribosome assembly and stability. As a part of the ribosomal complex RPL36A contributes to the decoding and translocation phases during protein biosynthesis. Its integration within this complex highlights its significance in cellular metabolism and growth.
- Pathways
RPL36A plays an integral part in the translation pathway specifically in the process of translation initiation and elongation. It is actively involved in the assembly of the pre-initiation complex and the elongation cycle. Additionally RPL36A interacts within the mTOR signaling pathway which regulates cell growth and metabolism in response to nutrients growth factors and other stimuli. Through this pathway its relationship with proteins like S6 kinase is noteworthy as they collectively influence protein synthesis rate and cell growth.
- Associated diseases and disorders
Alterations in RPL36A can potentially relate to cancer and Diamond-Blackfan anemia (DBA). Changes in the expression levels or mutations of RPL36A have been implicated in the development of certain cancers where enhanced ribosomal biogenesis supports tumor growth. In DBA a disorder characterized by failure in red blood cell production mutations in ribosomal proteins like RPL36A disrupt ribosome function leading to hematological abnormalities. Interactions with other ribosomal proteins such as RPS19 further illustrate its involvement in the pathogenesis of ribosomopathies.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Sanger Sequencing - Human RPL36A knockout HeLa cell line (ab265182)
Allele-1: 1 bp insertion in exon 1.
Sanger Sequencing - Human RPL36A knockout HeLa cell line (ab265182)
Allele-2: Insertion of the selection cassette in exon 1.
Sanger Sequencing - Human RPL36A knockout HeLa cell line (ab265182)
Allele-3: Insertion of the selection cassette in exon 1.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com